Editas Medicine stock last stood at EUR 2.15 on October 16, 2026, 45.00 percent below high

Published on 10/17/2026 at 20:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Earnings are scheduled for November 9, 2026. Editas Medicine stock stood at EUR 2.15 on October 16, 2026, 2.38 percent above the Tradegate close.

Price position and dates

Editas Medicine stock stood 45.00 percent below its 52-week high on October 16, 2026.
The next earnings report is scheduled for November 9, 2026.
Editas Medicine stock last stood at EUR 2.15 on October 16, 2026, 2.38 percent above the Tradegate close.
Editas Medicine had a market capitalization of USD 360.9 million as of October 16, 2026.

EDIT, US28106W1036, Illustration mit AI erstellt.

Editas Medicine stock stood 45.00 percent below its 52-week high of USD 4.28 on October 16, 2026, putting the biotechnology company firmly inside its current annual range. The next earnings report is scheduled for November 9, 2026, according to MarketBeat. Editas Medicine stock last stood at EUR 2.15 at Tradegate on October 16, 2026 at 3:33 p.m. CEST, 2.38 percent above the Tradegate close.

Annual range sets the frame

The Nasdaq-listed company ended the October 16 session at USD 2.35, down 3.69 percent from the previous close. Its 52-week range was USD 1.66 to USD 4.28, leaving the stock 45.00 percent below the upper boundary and 41.57 percent above the lower boundary.

Editas Medicine was up 14.60 percent year to date through October 16, 2026. Trading volume reached 1,551,219 shares against an average of 2,526,143 shares, while the session range ran from USD 2.33 to USD 2.44.

Valuation and upcoming dates

Editas Medicine had a market capitalization of USD 360.9 million on October 16, 2026. Its price-to-earnings ratio was negative 3.14, reflecting trailing losses, and the company paid no dividend yield. The November 9 reporting date gives investors the next scheduled checkpoint for revenue, cash use and clinical development updates.

On October 8, 2026, Editas Medicine had received approval to begin a first-in-human Phase 1/2 trial of EDIT-401 in Australia, according to FinanzNachrichten. The release said initial safety and tolerability data were expected in the first quarter of 2027. That program remains a central calendar item because the company is developing gene-editing medicines for serious diseases.

Comparison with peers

EDIT (Tradegate, EUR): plus 2.38 percent, P/E minus 3.14, market capitalization USD 360.9 million.
CRISPR Therapeutics (Nasdaq, USD): minus 4.41 percent, P/E minus 10.35, market capitalization USD 4.8 billion.
Intellia Therapeutics (Nasdaq, USD): plus 0.71 percent, P/E minus 3.40, market capitalization USD 1.6 billion.

Price and investor calendar

Editas Medicine's price position combines a 14.60 percent year-to-date gain with a 45.00 percent gap to its 52-week high. The November 9, 2026 results date is the next scheduled company event, while the October 8 trial approval remains the latest dated clinical milestone.

The latest available euro price stood at EUR 2.15 at Tradegate on October 16, 2026 at 3:33 p.m. CEST. The Nasdaq session ended at USD 2.35 on October 16, 2026 at 4:00 p.m. ET.